Pharmaceutical stocks are sought after the defensive qualities | Nearly 80% of pharmaceutical companies Q1 pre hi

Yesterday, in the broader market volatility adjustment, the biomedicine sector index hit another new high since the current round of rebound. Pharmaceutical stocks soared during the disclosure of the annual report. In addition to rising market risk appetite, it is more important for some pharmaceutical stocks to have good fundamentals and outstanding results. Expected results. Statistics show that as of yesterday, 115 pharmaceutical companies disclosed earnings forecasts for the first quarter of 2018, and the number of companies for the company's earnings forecast reached 88, accounting for 76.52%. Today's newspaper specializes in market funding, performance, and institutional ratings. 3. Analyze the investment opportunities of the pharmaceutical stocks in three areas, in order to readers.

"Securities Daily" Market Research Center found out from the statistics of flush data since April. medicine The performance of the bio-plate market was outstanding. The cumulative growth of the sector reached 1.55%. Only from the market performance yesterday, the medical and bio-sector rebounded against the market once again. The overall increase ranked at the top of the plate gains list.

Specifically, since April, 164 pharmaceutical bioequities have gained during the period, with 31 constituent stocks accumulatively increasing more than 10% during the period. Among them, GCL Investment (41.48%), Shuangcheng Pharmaceutical (38.46%), Dragon Pharmaceutical (37.50%), Jiudian Pharmaceutical (27.42%), Zhenghai Biological (21.92%), Shanhe Pharmaceuticals (20.37%) and other stocks have accumulated more than 20% during the period.

From the perspective of market performance yesterday, 130 pharmaceutical biological stocks have risen to varying degrees, accounting for nearly 50%. Among them, Yangpu Healthcare, Luohai Investment, and other two stocks have reached a strong daily limit, Zhifei Biological (8.61%), opened. Medical (8.17%), Sincere Pharmaceutical (8.04%), Shangrong Medical (7.22%), Cheung Seng Life (7.14%), Dongfulong (6.32%), Pien Tze Huang (5.65%), Runda Medical (5.45%) , Qianjin Pharmaceutical (5.39%), Opco (5.09%) and other stocks rose more than 5%.

With respect to capital flows, the Securities Research Center’s market research center found that according to statistics of flush data, since the month of April, 85 pharmaceutical biologicals stocks have experienced a net inflow of large single funds, total net inflows of large single funds of 1.979 billion yuan, of which, Tong Ren Tang, Dezhan The net inflows of large single funds during the period of two stocks such as health were all over 100 million yuan, which was: 116.5596 million yuan and 1100.9072 million yuan. From the perspective of the funds yesterday, 115 pharmaceutical biologic stocks were favored by large single funds. The net inflow of single funds was 1.3 billion yuan, of which, Pien Tze Huang (129,229,900 yuan), Lepu Medical (888,950,000 yuan), Leunghai Investment (6,363,230 yuan), Fosun Pharmaceutical (53,819,500 yuan), and Shangrong Medical (51,808,400 yuan). Yuan), Hengrui Medicine (50.1346 million yuan) and other 6 stocks have a net inflow of over 50 million yuan.

The excellent market performance of the medical and biotechnology sector has also received widespread attention from institutions. Since April, Sichuan Finance, Great Wall Securities, Guohai Securities and other institutions have issued research reports indicating continued optimism for the outlook of pharmaceutical bioequities. Among them, Zhejiang Securities It is believed that under the background of continuous advancement of medical reform, innovative drugs should be 'new', 'improved drugs' should be 'excellent', and generic drugs should be 'same' further implemented. Innovative drugs and consistency assessment as key areas of advancement are still the main investment lines for the future. In particular, follow-up policies continue to follow, high-quality innovative drugs enterprise And there is a large imitation of imitation products, is expected to expand the share through the consistency assessment of generic pharmaceutical companies in need of value revaluation.

"Securities Daily" Market Research Center found that according to the statistics of the same flush, as of April 12, a total of 137 companies listed in the pharmaceutical biotechnology industry disclosed the 2017 annual report, of which, 113 companies had a year-on-year increase in net profit in 2017, accounting for 82.48%.

Specifically, of the 113 companies mentioned above, which saw a year-on-year growth in net profit in 2017, 12 companies’ net profits doubled year-on-year in 2017, Zhifei Bio (1229.25%), Beilu Pharmaceutical (625.40%), Livzon Group (464.63). %) , health Yuan (372.52%), Tiantan Bio (359.33%) and other companies' net profit increased by more than 300% year-on-year in 2017.

It is worth mentioning that, as the 2017 annual report was released on a large scale, performance reports for the first quarterly and quarterly reports in 2018 were also released. As of April 12, Haisike, Puluo Pharmaceutical, Rentongtai, etc. Both have disclosed their results in the first quarter of 2018 and their net profit in the first quarter has achieved year-on-year growth. In addition, 115 companies have disclosed earnings forecasts for the first quarter of 2018, and the company has achieved a total of 88 companies, accounting for 76.52%.

Looking further, it was found that 41 companies are expected to achieve the 2017 annual report, and their net profit will increase in the first quarter of 2018. Among them, Garden Bio, Jindawei, Zhifei Bio, Zixin Pharmaceutical, PuLi Pharmaceutical, Zhenghai Bio, Harbin Sanlian, Twelve companies such as Chenxin Pharmaceutical, Haichen Pharmaceutical, Yongan Pharmaceutical, Kailim Medical, and Essence Pharmaceutical are expected to double their net profits in the first quarter of 2018 while achieving year-on-year growth in net profit in 2017. .

"Securities Daily" Market Research Center found that according to the statistics of flush data, the performance of the pharmaceutical sector as a whole is better, with higher defensive characteristics, and the market is highly concerned. In the past 30 days, a total of 105 pharmaceutical bio stocks have been given a 'buy' by the agency. Or 'accelerate' and other bullish ratings, 23 stocks institutions are optimistic about the number of ratings are at 10 or more.

Specifically, three stocks institutions such as East China Pharmaceutical, Tasly, and Livzon Group are optimistic that the number of ratings will reach 20 or more, namely: 22, 21, 20, Yifeng Pharmacy (19), Lepu Medical (19), Sinopharm Accord (17), Rongtai Health (17), Anke Bio (17), Zhifei Bio (17), Shanghai Pharmaceutical (17), Hualan Bio (16) Among the 10 stocks, 15 stocks, including Donga Ejiao (15) and Huahai Pharmaceutical (15), all 15 or more institutions are also getting bullish. Other institutions are bullish on stocks with ratings of 10 and above: Antu Biology, Litai, ordinary people, Chinese medicine, China Resources Sanjiu, Sinopharm, China Resources Shuanghe, Liuzhou Pharmaceutical, Yifan Pharmaceutical, Fosun Pharma.

As the organization's most promising pharmaceutical bio stocks, Huadong Medicine's net profit rose by 23.01% year-on-year in 2017. Its main business revenue increased by 9.66% year-on-year, and its net asset yield was 23.02%. Everbright Securities stated that the company is a high-quality Baima stock and its main varieties are growing steadily. , Research pipelines are abundant. R&D expenditure investment is slightly higher than expected, and slightly downward adjustment is expected from 2018 to 2020 earnings per share of 2.26 yuan, 2.80 yuan, 3.45 yuan, respectively, year-on-year growth of 23%, 24%, 23%, The current stock price corresponds to 29 times 2018 earnings and maintains the 'overweight' rating.